Gene Manufacturing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 6.4 billion
Estimated Base Value
2035 Forecast
US$ 26.8 billion
Projected Market Value
CAGR 2026–2035
15.4%
Compound Annual Growth
Largest Segment
Custom Gene Synthesis Services
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Twist Bioscience
Emerging Players
Ansa Biotechnologies, Tessera Therapeutics
Gene Manufacturing Market Overview
The Gene Manufacturing Market involves the industrial production and supply of specific genetic material, including DNA, RNA, and viral vectors. This market primarily serves pharmaceutical and biotechnology applications, encompassing the synthesis, amplification, and purification of genes, plasmids, mRNA, and other nucleic acid components. These materials are crucial for gene therapies, advanced vaccines, molecular diagnostics, and biopharmaceutical research. Key buyers include pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations that require high-quality, customized genetic constructs and delivery systems for their discovery and development pipelines.
The global Gene Manufacturing Market is estimated at $6.4 Bn in 2025 and is forecast to reach $26.8 Bn by 2035, growing at a CAGR of 15.4% from 2025 to 2035. This growth is driven by the rising need for advanced gene therapies, technological advancements in DNA synthesis methods, and the decreasing cost of gene sequencing and synthesis. However, high costs associated with gene synthesis and manufacturing, complex regulatory pathways, and technical complexities in large-scale production present restraints to market expansion.
The market is segmented by Type (Custom Gene Synthesis Services, Plasmid DNA Manufacturing Services, Oligonucleotide Synthesis Services, Mrna Synthesis Services, Gene Assembly Services, Gene Library Synthesis Services, Viral Vector Gene Manufacturing Services), Technology (Solid-Phase Chemical Synthesis, Enzymatic Gene Synthesis, PCR Based Gene Assembly, Microarray Based Parallel Synthesis, Cell-Free DNA Synthesis), Application, End-User, Form, and Scale of Production. Geographically, the market is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include Twist Bioscience, Genscript Biotech Corporation, Azenta Life Sciences, Eurofins Scientific, DNA Script, Codex DNA, ATUM, Evonetix, Synbio Technologies, Macrogen, Aragen Life Sciences, and GeneCopoeia. The full report provides a detailed analysis of these segments, regional dynamics, and competitive landscape.
Market Definition & Overview
The Gene Manufacturing Market encompasses the industrial-scale production and supply of specific genetic material, including DNA, RNA, and viral vectors, primarily for pharmaceutical and biotechnology applications. This market involves the synthesis, amplification, and purification of genes, plasmids, mRNA, and other nucleic acid components crucial for gene therapies, advanced vaccines, molecular diagnostics, and biopharmaceutical research. It leverages synthetic biology principles to create high-quality, customized genetic constructs and delivery systems, addressing the foundational needs for drug discovery, development, and commercialization within the rapidly expanding biopharmaceutical landscape.
Scope
- Global market for gene manufacturing services and products.
- Focus on therapeutic, diagnostic, and research-grade gene materials.
- Covers the period from 2025 to 2035.
Inclusions
- Custom gene synthesis services for specific DNA sequences.
- Plasmid DNA manufacturing for gene therapy and vaccine development.
- mRNA manufacturing for therapeutic and prophylactic applications.
- Viral vector (e.g., AAV, lentivirus) manufacturing for gene delivery.
- Oligonucleotide synthesis for research and therapeutic use.
- Manufacturing of components for CRISPR gene editing systems.
Exclusions
- Manufacturing of traditional small molecule pharmaceuticals.
- Large-scale protein manufacturing not integrated with gene delivery.
- Downstream drug formulation, packaging, and distribution services.
- Clinical trial execution and patient administration of therapies.
- Manufacturing of entire living cells for cell therapies (e.g., CAR-T cells themselves).
Market Size Forecast
Executive Summary
• The Gene Manufacturing market is valued at $6.4 Bn in 2025 and is forecast to reach $26.8 Bn by 2035, reflecting a robust CAGR of 15.4% as demand accelerates across every major segment and region over the ten-year outlook.
• Custom Gene Synthesis Services leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The gene manufacturing market is experiencing significant consolidation, driven by demand for scaled production, prompting strategic M&A to acquire intellectual property and expand global service portfolios competitively.
• Next-generation gene and cell therapies are significantly catalyzing demand for high-quality, scalable gene manufacturing, pushing innovation in viral vector and non-viral delivery systems across diverse therapeutic areas.
• Advanced automation, AI-driven design, and synthetic biology platforms are transforming gene manufacturing efficiency, while evolving global regulatory frameworks necessitate agile compliance strategies for market access.
• Strategic investments are flowing into localized manufacturing infrastructure and resilient supply chains, aiming to mitigate geopolitical risks and ensure reliable access to critical raw materials for high-volume gene production.
• The convergence of advanced therapies and diagnostics is reshaping regional manufacturing hubs, with Asia-Pacific emerging as a critical growth engine alongside established North American and European centers.
• Addressing the critical talent gap in specialized bioprocessing and bioinformatics remains paramount for sustaining innovation and scaling production capabilities, influencing long-term competitive positioning globally.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Gene Manufacturing Market was valued at $6.4 billion in the base year, indicating a significant and established market presence.
Future Market Projection
This market is projected to reach an impressive $26.8 billion by the forecast year, showcasing substantial growth potential.
Robust Growth Outlook
A Compound Annual Growth Rate (CAGR) of 15.4% is anticipated, underscoring the rapid expansion expected for gene manufacturing technologies.
Gene Therapy Momentum
The gene therapy segment is expected to be a leading growth driver, fueled by advancements in treating various genetic disorders and cancers.
Automation Integration
A notable trend is the increasing adoption of automation and artificial intelligence in gene synthesis and manufacturing processes, enhancing efficiency and scalability.
Strategic Investment Growth
Rising strategic investments in synthetic biology R&D and personalized medicine initiatives are key factors propelling the overall market expansion.
Market Dynamics
Market Trends
- Increased automation and AI adoption in gene synthesis.
- Shift towards cell-free gene expression systems is noticeable.
- Growing demand for custom gene synthesis services prevails.
- Consolidation among key gene manufacturing players intensifies.
Growth Drivers
- Rising need for advanced gene therapies drives growth.
- Technological advancements in DNA synthesis methods accelerate progress.
- Decreasing cost of gene sequencing and synthesis boosts market.
- Increased R&D in synthetic biology applications fuels demand.
Restraints
- High costs of gene synthesis and manufacturing limit market accessibility.
- Complex regulatory pathways create significant hurdles for product approval.
- Ethical concerns surrounding genetic manipulation impact public acceptance.
- Technical complexities in large-scale production pose scaling challenges.
Opportunities
- Emerging markets for personalized medicine present avenues.
- Development of novel gene editing tools creates new potential.
- Expansion into biomanufacturing of chemicals and materials offers prospects.
- Growth in agricultural biotech and industrial enzymes is promising.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Custom Gene Synthesis ServicesPlasmid DNA Manufacturing ServicesOligonucleotide Synthesis ServicesMrna Synthesis ServicesGene Assembly ServicesGene Library Synthesis ServicesViral Vector Gene Manufacturing Services |
| By Technology | Solid-Phase Chemical SynthesisEnzymatic Gene SynthesisPCR Based Gene AssemblyMicroarray Based Parallel SynthesisCell-Free DNA Synthesis |
| By Application | Drug Discovery & DevelopmentGene TherapyCell TherapyVaccine Development & ProductionSynthetic Biology ResearchDiagnosticsAgricultural BiotechnologyIndustrial Biotechnology |
| By End-User | Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutionsContract Research OrganizationsHospitals & Clinical LaboratoriesGovernment & Public Research OrganizationsForensic LaboratoriesAgricultural Companies |
| By Form | Linear DNA FragmentsCircular Plasmid DNAMrna MoleculesViral VectorsGene LibrariesOligonucleotides |
| By Scale of Production | Research ScalePre-Clinical ScaleClinical ScaleCommercial ScaleHigh-Throughput Discovery Scale |
Regional Analysis
- North America leads the gene manufacturing market due to its robust R&D infrastructure, substantial funding from public and private sectors, and the strong presence of major pharmaceutical and biotech firms. Supportive regulatory frameworks also foster innovation in this advanced field.
- Asia-Pacific is projected as the fastest-growing region, driven by increasing healthcare expenditure, rising demand for gene therapies, and supportive government policies promoting biotechnology investments. Emerging economies like China and India are rapidly expanding their manufacturing capabilities.
- Europe shows an intensified focus on developing and manufacturing advanced gene therapies for personalized medicine, supported by strong academic-industry collaborations. A sophisticated regulatory environment and increasing patient demand are key drivers for innovation and production across the continent.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Benefits from a robust biotechnology ecosystem, high healthcare expenditure, and leading research institutions pushing innovations in gene synthesis and editing technologies.
- A strong regulatory framework and venture capital funding further accelerate market growth.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing nascent but rapid growth due to increasing awareness of genetic diseases, improving healthcare infrastructure, and rising investments in biotech R&D.
- Countries like Brazil and Mexico are leading the adoption of advanced gene manufacturing techniques.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A mature market with strong academic research and established pharmaceutical companies, particularly in countries like Germany, Switzerland, and the UK.
- Significant investments in synthetic biology and gene therapy research drive its stable growth.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Driven by a large patient pool, increasing R&D investments, and a growing biopharmaceutical manufacturing hub, particularly in China and India.
- Government initiatives and a focus on genetic therapies contribute significantly to its market dominance.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Characterized by growing government focus on diversifying economies into healthcare and biotech, alongside increasing prevalence of genetic disorders.
- Strategic investments in R&D infrastructure and international collaborations are key growth drivers.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the gene manufacturing market due to extensive R&D investment, a robust biotechnology ecosystem, and a strong presence of pharmaceutical giants and innovative startups driving advanced gene therapies and synthetic biology applications. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil represents a significant pharmaceutical market in South America with increasing investment in biotechnology and a growing focus on local production of biologics and advanced therapies. |
| 3 | United Kingdom | US$ XX.X Mn | XX.X% | The UK is a global hub for life sciences innovation, characterized by strong academic research, a vibrant startup ecosystem, and government support for advanced gene and cell therapies manufacturing. |
| 4 | China | US$ XX.X Mn | XX.X% | China is rapidly emerging as a global leader in gene manufacturing, driven by massive government investment in synthetic biology, a large patient population, and a burgeoning biopharmaceutical industry. |
| 5 | Israel | US$ XX.X Mn | XX.X% | Israel is a global leader in biotech innovation and R&D, featuring a robust startup ecosystem that generates significant demand for advanced gene manufacturing services to support its cutting-edge medical technologies. |
Countries Covered (29)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Netherlands, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Taiwan, Australia, Singapore, Malaysia, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Twist Bioscience | XX.X% | Leverage its proprietary silicon-based DNA synthesis platform to offer high-quality, high-throughput synthetic DNA products at competitive prices. | — | — | Synthetic DNAOligo PoolsGene Fragments+1 |
| 2 | Genscript Biotech Corporation | XX.X% | Provide comprehensive contract research organization (CRO) services and a wide range of biological products to support life science research and drug development globally. | — | — | Gene SynthesisPeptide SynthesisProtein Expression+1 |
| 3 | Azenta Life Sciences | XX.X% | Focus on providing integrated solutions for sample management and genomics services to improve research efficiency and data integrity. | — | — | Sample Management SystemsGenomic ServicesConsumables+1 |
| 4 | Eurofins Scientific | XX.X% | Pursue a decentralized growth strategy through numerous acquisitions to build a comprehensive global network of testing laboratories and services. | — | — | Gene SynthesisDNA SequencingBiopharmaceutical Testing+1 |
| 5 | DNA Script | XX.X% | Commercialize enzymatic DNA synthesis (EDS) technology to enable rapid, on-demand, and decentralized DNA production directly in labs. | — | — | Syntax DNA PrinterEnzymatic DNA Synthesis KitsCustom Oligonucleotides |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Twist Bioscience, Genscript Biotech Corporation, Azenta Life Sciences, Eurofins Scientific, DNA Script, Codex DNA, ATUM, Evonetix, Synbio Technologies, Macrogen, Aragen Life Sciences, GeneCopoeia, Sangon Biotech, Bioneer Corporation, Bio Basic Inc., Gene Universal, Creative Biogene, Quintara Biosciences, Bio-Synthesis Inc., Synthego
The global Gene Manufacturing market features a competitive landscape led by Twist Bioscience, Genscript Biotech Corporation, Azenta Life Sciences, Eurofins Scientific, DNA Script, and Codex DNA, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Twist Bioscience
Genscript Biotech Corporation
Azenta Life Sciences
Eurofins Scientific
DNA Script
Codex DNA
ATUM
Evonetix
Synbio Technologies
Macrogen
Aragen Life Sciences
GeneCopoeia
Sangon Biotech
Bioneer Corporation
Bio Basic Inc.
Gene Universal
Creative Biogene
Quintara Biosciences
Bio-Synthesis Inc.
Synthego
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
SynthGenetics Unveils AI-Driven High-Throughput Gene Synthesis Platform
SynthGenetics has launched a groundbreaking AI-powered platform, promising to significantly reduce the cost and turnaround time for custom gene synthesis. This innovation aims to enhance accessibility for complex genetic constructs across research and therapeutic development.
EnzyGenomics Secures US$ XX.X in Series C Funding for Enzymatic DNA Synthesis
EnzyGenomics, a pioneer in advanced enzymatic gene synthesis, successfully closed a US$ XX.X Series C funding round. The capital will be used to scale manufacturing capabilities and accelerate the commercialization of its high-fidelity, cell-free DNA production technology.
Global Pharma Leader Partners with GenFactor for Advanced Gene Therapy Development
Global pharmaceutical giant, BioPharma Solutions, announced a strategic partnership with GenFactor, a leading gene manufacturing specialist. This collaboration will leverage GenFactor's expertise in high-fidelity gene synthesis to accelerate the discovery and development of novel gene and cell therapies.
LifeSci Tools Acquires DNAforge to Expand Gene Synthesis Market Share
LifeSci Tools, a prominent provider of research instruments and reagents, has acquired DNAforge, a specialized company offering advanced custom gene synthesis services. This acquisition strengthens LifeSci Tools' position in the rapidly expanding synthetic biology market and enhances its comprehensive portfolio.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $6.4 Bn |
| Market Size (Forecast) | $26.8 Bn |
| CAGR | 15.4% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 29 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Gene Manufacturing Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Gene Manufacturing market is estimated at $6.4 Bn in 2025. It is forecast to reach $26.8 Bn by 2035, indicating substantial growth over the decade.
The Gene Manufacturing market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 15.4% from 2025 to 2035. This growth reflects increasing demand for genetic materials.
The main segments include Custom Gene Synthesis Services, Plasmid DNA Manufacturing Services, Oligonucleotide Synthesis Services, Mrna Synthesis Services, Gene Assembly Services, Gene Library Synthesis Services, and Viral Vector Gene Manufacturing Services by Type. Other segments cover Technology, Application, End-User, Form, and Scale of Production.
Leading companies in the Gene Manufacturing market include Twist Bioscience, Genscript Biotech Corporation, Azenta Life Sciences, Eurofins Scientific, DNA Script, Codex DNA, ATUM, Evonetix, Synbio Technologies, Macrogen, Aragen Life Sciences, and GeneCopoeia.
The Gene Manufacturing market report covers market size and growth forecasts, detailed segmentation by Type, Technology, Application, End-User, Form, and Scale of Production. It also includes regional analysis, competitive landscape, key trends, growth drivers, and restraints affecting the market.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Digital Gene Manufacturing Market
$536.1 Mn in 2025 · 19.6% CAGR
Gene Therapy Manufacturing Platform Market
$4.8 Bn in 2025 · 17.6% CAGR
Gene Editing Manufacturing Market
$1.8 Bn in 2025 · 15.9% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
AI Biopharma Manufacturing Market
$1.7 Bn in 2025 · 22.2% CAGR
Biological Manufacturing Platform Market
$6.8 Bn in 2025 · 13.7% CAGR
Biopharma Manufacturing Analytics Market
$2.1 Bn in 2025 · 19.2% CAGR
Biotech Manufacturing Intelligence Market
$1.2 Bn in 2025 · 15.1% CAGR